Section Editor: Kianoosh Keyhanian MD FRCPC
May 25, 2026
Endometrioid borderline tumor is a type of ovarian tumor that is not cancer, but is also not a completely benign growth. It belongs to a group of tumors called borderline tumors, which sit between clearly benign tumors and cancer. The behavior of an endometrioid borderline tumor falls somewhere between an endometrioid cystadenofibroma, which is a benign (noncancerous) tumor, and endometrioid carcinoma, which is a type of ovarian cancer. The tumor is called “endometrioid” because, under the microscope, its cells resemble those that normally line the inside of the uterus (the endometrium).
Endometrioid borderline tumor is the third most common type of borderline ovarian tumor, after the serous and mucinous types, although it is much less common than either of those. It is usually found in only one ovary, and most cases are diagnosed in women in their 50s. The outlook is excellent, and most patients are cured by surgery alone.
This article will help you understand what this diagnosis means on your pathology report, what each term means, and why it matters for your care.
The exact cause of endometrioid borderline tumor is not known. The most important known association is with endometriosis, a condition in which tissue similar to the lining of the uterus grows outside the uterus, including on or within the ovary. Many patients with an endometrioid borderline tumor have a history of endometriosis, or their ovary shows evidence of endometriosis when it is examined under the microscope.
For this reason, it is believed that in some women, endometriosis acts as the “seed” from which an endometrioid borderline tumor develops. It is important to keep this risk in perspective: endometriosis is common, and the great majority of women who have endometriosis will never develop an endometrioid borderline tumor or any ovarian cancer. The tumor cells often contain changes (mutations) in genes such as CTNNB1 and PTEN, which are involved in controlling how cells grow. There are no clearly established lifestyle causes.
Many endometrioid borderline tumors cause no symptoms and are discovered during an imaging test or examination performed for another reason. When symptoms do occur, they are usually related to the presence of a mass in the ovary and may include:
Some patients also have symptoms related to endometriosis, such as painful menstrual periods or long-standing pelvic pain. Because these symptoms are common and can have many causes, they are not specific to endometrioid borderline tumor. Any persistent abdominal or pelvic symptom should be evaluated by a doctor.
For most women, the diagnosis of an endometrioid borderline tumor is made after the entire tumor is surgically removed and sent to a pathologist for examination under the microscope. The fallopian tube on the same side, and sometimes the uterus and other tissues, may be removed at the same time, depending on the situation.
During the operation, the surgeon may request an intraoperative consultation (also called a frozen section). In this situation, the pathologist examines a sample of the tumor while the patient is still in the operating room and provides a preliminary diagnosis within minutes. The result of an intraoperative consultation can change the type of surgery performed or the treatment offered afterward. A final diagnosis is made later, once the entire tumor has been examined in detail.
When examined under the microscope, an endometrioid borderline tumor shows several characteristic features:
While examining the tumor, the pathologist looks for two specific findings that are sometimes seen in an endometrioid borderline tumor:
Based on current evidence, the presence of intraepithelial carcinoma or microinvasion in an endometrioid borderline tumor does not appear to meaningfully change the outlook when the tumor is confined to the ovary and completely removed. These findings are recorded in the pathology report and may prompt closer follow-up.
All ovarian tumors are examined to see whether there are any holes or tears in the outer surface of the tumor or ovary. This outer surface is called the capsule.
The pathologist also examines the surface of the ovary under the microscope to determine whether any tumor cells are present. A ruptured capsule or tumor cells on the surface of the ovary raise the pathologic stage because both increase the chance that tumor cells could reach other surfaces in the abdomen or pelvis.
Lymph nodes are small immune organs located throughout the body. The risk that an endometrioid borderline tumor will spread to lymph nodes is very low. For this reason, lymph nodes are often not removed during surgery for this type of tumor. If lymph nodes are removed, the pathologist examines them under the microscope and reports the number examined and, if any, the number that contain tumor cells.
Even though an endometrioid borderline tumor is not cancer, it is given a pathologic stage using the same system used for ovarian cancers, the FIGO staging system. The stage describes how much of the tumor was found beyond the ovary itself. The great majority of endometrioid borderline tumors (approximately 90%) are stage I, meaning the tumor is confined to the ovary.
To help determine the stage, small tissue samples, called biopsies, may be taken during surgery from the omentum (a sheet of fatty tissue over the intestines) and the peritoneum (the lining of the abdominal cavity), and fluid may be collected from the abdomen. These are examined for tumor cells.
The prognosis for endometrioid borderline tumor is excellent. The great majority of these tumors are confined to one ovary at the time of diagnosis, and surgical removal alone is curative for nearly all patients. Recurrence and spread to other organs are uncommon. As noted above, even when the tumor contains areas of intraepithelial carcinoma or microinvasion, the outlook for a tumor that is confined to the ovary and completely removed remains very good.
A few factors are associated with a need for closer follow-up:
Surgery is the main treatment for endometrioid borderline tumor, and for most patients it is the only treatment needed. The discussion between you and your gynecologic team about the type of surgery depends on your age, whether you wish to preserve the ability to become pregnant, and the findings on your pathology report.
Options that the team may discuss include:
After treatment, follow-up with a gynecologist or gynecologic oncologist is recommended to promptly identify and manage any recurrence.